T hroughout oral and recorded history, the fetus has maintained an enigmatic presence, with its development in the womb the subject of folklore and scientific inquiry alike. However, modern-day advances, particularly in imaging technology, have provided a window through which to view fetal life, defining first the events of natural growth and second, by comparison, revealing irregular development. The goal of this article is (1) to provide a historical perspective of fetal treatment, including the development and evolution of fetal surgery, and describe some milestones of this multifaceted, complex area; (2) to detail the components and dynamics of collaborative team management of fetal therapy patients; and (3) to introduce emerging trends that will affect the future of this rapidly evolving field.
HISTORICAL PERSPECTIVE
In the 1950s and 60s, the use of ultrasonography manifested as a powerful diagnostic and imaging tool that could be used to determine and thus document gestational age, fetal growth patterns, fetal well-being, amniotic fluid levels, and the position of the placenta. Perhaps, more critical, as a diagnostic tool, it could also detect what deviated from the norm, that is, ultrasonography could reveal the presence of certain congenital anomalies-a capability that particularly and inextricably linked it to fetal diagnosis and treatment. Ultrasonography also proved to be an essential adjunct to other diagnostic procedures, for example, amniocentesis, chorionic villus sampling, and percutaneous umbilical blood sampling. These techniques, in conjunction with or guided by ultrasonography, laid the groundwork for the new frontier of fetal treatment. Once abnormal fetal conditions could be discovered early, the possibility that many of them could be amenable to prenatal treatment could be courted. And, indeed these therapies before birth were explored, developed, rigorously tested in animal models, and demonstrated to be efficacious. No longer were management options limited to postnatal treatment (when some irreversible degree of morbidity may have already occurred) or termination of the pregnancy. Thus, the fetus became a patient.
Although ultrasound is and will remain the primary fetal diagnostic and monitoring tool, magnetic resonance imaging (MRI), a noninvasive procedure that uses powerful magnets and radio waves to construct images of the body, is establishing a niche in fetal therapy with its ability to provide more information in situations where ultrasound does not. Where fetal motion once limited MRI's use for obstetric imaging, advances in MRI techniques have addressed and virtually eliminated this problem. As a result, the use of MRI, particularly fetal brain imaging, has increased significantly, leading to earlier diagnosis of fetal anomalies, and thus has proved useful in planning fetal surgery as well as The first attempt at amelioration of a fetal condition was prompted by the design of a strategy to treat erythroblastosis fetalis, a life-threatening fetal and neonatal complication in which the mother produces antibodies that attack the fetus's red blood cells. In 1963, New Zealand clinician-scientist A.W. Liley performed an in utero, fluoroscopy-guided exchange transfusion of red blood cells into the abdomen of a 32-week fetus to replenish the fetus's own supply. 1, 2 This procedure was heralded as paving a new direction in medical therapeutics and thus initiating a new era in obstetric and pediatric care. Liley's work effectively marked the birth 13 of fetal treatment-the in utero medical intervention or correction of a fetal condition.
Fetal therapy at the University of California, San Francisco (UCSF) was conceived and developed experimentally beginning in 1978, and came to clinical fruition in 1981. The enterprise in its conceptual stage began as a meeting of the minds of a talented obstetrician/ geneticist, Dr Mitchell Golbus, an skillful sonographer/radiologist, Dr Roy Filly, and an inquisitive pediatric surgeon, Dr Michael Harrison. While Dr Golbus was seeing a growing number of fetal anomalies identified in his prenatal diagnosis clinic and via his AFP screening and genetic counseling program, coincidentally, Roy Filly, with his colleagues, Peter Callen and Ruth Goldstein, were establishing a premier fetal ultrasound unit and systematically documenting the natural history of a wide variety of fetal malformations. In the meantime, Dr Harrison, who operated on many newborns already ravaged by their fetal disease by the time of birth, was in the research laboratory, wondering whether it was possible to prevent some of these problems with fetal intervention. Coming from disparate disciplines and certainly with different temperaments, they were physicians who believed that they could do something that had not yet been seriously attempted.
All this information (the clinical problems, the natural history of fetal disease, the experimental inquiry and hypotheses, and clinical rationale) would come together every week at a noon joint OB/Neonatology conference, which was originally established to coordinate high-risk deliveries. Dr Harrison, as a pediatric surgeon, began to attend this weekly meeting. He started presenting neonatal surgical cases to stimulate discussion about whether a particular defect could be found early on and perhaps even dealt with before birth. Cultivated by Filly's sonographic diagnoses, Golbus's screening techniques, and Harrison's experimental work, these discussions proved fertile ground for questions and new ideas. Each new clinical problem and every new proposal for management was vetted, argued, and discussed by the group that included representatives from neonatology, obstetrics, nursing, surgery, anesthesia, radiology, cardiology, and social work. This simple mechanism of a weekly multidisciplinary conference, like that of a tumor board, allowed anecdotal and documented experiences to be shared, provided coordinated strategies for excellent clinical care, cultivated new ideas to be discussed and challenged, and, most important, allowed professionals from widely different backgrounds and temperament to work together.
While the Fetal Treatment Center research group studied a variety of fetal diseases in animal models, including diaphragmatic hernia, urinary tract obstruction, gastroschisis, hydrocephalus, and intrauterine growth retardation, the first disease to attract serious attention as a possible target for fetal intervention was fetal hydronephrosis, specifically bladder outlet obstruction in males with posterior urethral valves. Fetal hydronephrosis was one of the first and easiest diseases to detect sonographically, and the course of the disease before and after birth was sufficiently known. The investigators demonstrated in the laboratory and then in human fetuses that, without intervention, a severe obstruction would produce oligohydramnios and pulmonary hypoplasia and consequently progress to renal failure. They thought that the disease would be relatively easy to treat because all that was needed was to decompress the bladder before birth in the same way that it was already being decompressed after birth, either with a catheter shunt or with a surgical opening. The first successful fetal intervention for urinary tract obstruction was performed using placement of a double pigtail shunt (Harrison Fetal Bladder Stent, product #C2617; Cook Urologic, Spencer, Ind) in a procedure that taught the team how to orchestrate and utilize the talents of a perinatologist, sonographer, and surgeon together.
At about the same time the first open fetal surgery case for urinary obstruction was performed, the Fetal Treatment team was presented a desperate fetal case of complete oligohydramnios, where decompression of the completely obstructed bladder at 18 weeks' gestation could be accomplished only through a hysterotomy and open vesicostomy. While the open surgical procedure was a success, the fetus never made urine, undoubtedly because intervention was too late and the kidneys were already dysplastic.
Catheter-shunt placement and open surgery for treatment of urinary tract obstruction were introduced simultaneously. Fortunately, both approaches were successes that demonstrated technical feasibility and, of crucial importance, initial safety for mothers. Over the course of the next 2-plus decades, the techniques, devices (shunts), and selection criteria have greatly improved through a vast and ongoing amount of work initiated at UCSF and continued very successfully around the world.
Founding of International Fetal Medicine and Surgery Society: 1981--1985
The first open fetal surgery and an increasing number of catheter-shunt placements being performed for obstructive uropathy at UCSF, coupled with first news of catheter-shunt interventions for hydrocephalus in Denver and several other centers in the United States, signaled that fetal surgery was not only off to a fast start, but potentially a precarious and vulnerable one. When publication of these first cases attracted considerable media attention, there was concern that the enterprise of fetal therapy could face latent disaster, for example, a media frenzy, controversy, and meltdown similar to that which accompanied the first human heart transplants in the late 1960s. Recognizing that this endeavor could be misrepresented, undermined, and easily destroyed by misinformation and too much exposure, the enterprise would have to be nurtured very carefully in terms of dealing with ethical issues and public perception. Early practitioners around the world made a wise, concerted, and conscious effort to band together, share information, discuss new techniques and treatment strategies, establish ethical guidelines, and agree and adhere to a set of strict standards for intervention. The fetal therapy community would oversee itself, but it would do so under the most rigorous conditions.
In early 1981, a meeting was held in which the UCSF group invited 24 experts from around the world for a 5-day conference. Discussion at the meeting encompassed every aspect of this enterprise of fetal therapy: from physiology to genetics to techniques of intervention. There was also frank discussion of self-imposed "rules to live by" which the entire group came to consensus and accepted. Specifically, the group agreed that (1) results should be published in peer-reviewed journals before given general media exposure; (2) attempts at intervention should be reserved for lethal diseases in which the pathophysiology and natural history of the untreated problem were understood; and (3) there would be strict adherence to ethical guidelines.
The following year the group formally established itself as the International Fetal Medicine and Surgery Society (IFMSS), a group that continues to meet annually, alternating between locations in the United States and around the world. Several years later, the group initiated publication of a specialty journal, Fetal Diagnosis & Therapy, which serves as the official voice of the IFMSS.
A precedent set at this first meeting and reinforced in subsequent meetings of the IFMSS was that the participants willingly shoulder the heavy responsibility for stewardship of the enterprise. At that first meeting, the participants by consensus created a framework for fetal intervention (eg, requirements for undertaking fetal intervention; strictures about publishing all cases good or bad before they appear in the media), and published this framework in the New England Journal of Medicine, 3 which set a high tone and a high standard for coming years. The IFMSS membership established a registry for fetal interventions and later published the early results with shunts for hydrocephalus and hydronephrosis, again, in the New England Journal of Medicine. 4 This widely referenced document laid out much of the collective thinking, and led to a voluntary moratorium on shunts for hydrocephalus that held for almost 2 decades, something of which the international fetal medicine community can be proud.
UCSF fetal treatment center early milestones
Encouraged by the successful efforts in treating urinary obstruction, the team continued its work in fetal intervention. Research efforts explored the technical aspects of fetal access and control of preterm labor. This exploration is best demonstrated in the ambitious undertaking of trying to treat infants with congenital diaphragmatic hernia (CDH), in whom viscera had herniated into the chest and prevented lung growth. The initial hypothesis and rationale of early intervention was simple: Total surgical repair in the fetus would allow room for the lung to grow. Using a variety of methods to successfully create CDH in fetal animal models, this in utero surgery strategy worked experimentally. But when clinical repair was first attempted in 1984, the group encountered the unfixable anatomic problem of liver herniated into the chest ("liver up"). Attempts to address this problem of liver proved immensely frustrating and discouraging. Where there was no liver herniation, surgical techniques eventually proved successful in CDH infants (1986), and those outcomes represented the first real breakthrough for fetal surgery. After a few successful cases established proof of concept, the National Institutes of Health funded UCSF Fetal Treatment Center's application to conduct a prospective, randomized clinical trial comparing open fetal surgery for total repair of CDH to the standard intensive therapy after birth (including ECMO). NIH sponsorship put the fetal clinical enterprise on the map, and the conduct of the trial was a "coming of age."On the surface, the trial appeared to be a straightforward study with a disappointing but interesting result: Open fetal surgical repair worked in those fetuses who did not have the liver herniated, but was no better than postnatal care in terms of survival rates. 5 So, while the results of the first NIH-sponsored clinical trial of treatment of fetal CDH may appear disappointing, the more profound significance of the trial was to subject a fetal intervention to the rigors of a proper prospective trial before the procedure is merely adopted and applied universally without appropriate testing. Table 2 summarizes the milestones in fetal treatment.
Fetus as patient: Maternal-fetal risks and benefits
Prenatal treatment of the fetus presents a formidable yet exciting challenge, but fetal surgery is predicated on a profound responsibility to the mother to ensure safety, because she, along with her unborn child, is a patient. The risk-benefit ratio of antenatal intervention favors the fetus with a lethal malformation, because without intervention, the mortality rate is almost uniformly 100%; with intervention, survival is possible. Justifying risk(s) is more difficult for the mother whose physical health usually is not jeopardized by her unborn baby's condition. Before clinical application of fetal surgery could be considered, it had to be proved that any intervention through the mother would not imperil her safety nor affect her future reproductive potential. 6 As a result, the safety of fetal surgical procedures were tested first in the most rigorous animal model, the nonhuman primate (monkey), because its anatomy and physiology most closely resembles that of the human pregnancy.
In consideration of preserving the mother's reproductive capability, the ability to deliver subsequent pregnancies was evaluated by a recent, retrospective study. 7 Complications were reported in 35% of pregnancies of women who had undergone maternal-fetal surgery. The anticipated risk of certain adverse outcomes has led to several recommendations, including longer interpregnancy intervals and cesarean section in the current pregnancy and subsequent pregnancies.
Moreover, it is important again to advise the maternal/ fetal surgery candidate of the risks in both the current and future pregnancies. 6 However, maternal results have not been sufficiently measured to fully analyze the efficacy and safety of maternal fetal surgery for patients; thus, maternal and fetal well-being both need to be measured in future studies. 8 
Ethical considerations
Fetal therapy presents new, often complex ethical dilemmas, rife with challenging questions and controversy, as the very nature of this therapy involves operating on one patient, the fetus, located within another patient, the mother. 9 Balancing is required. The outcomes of fetal surgery have improved over the past decade, yet the neonatal management of anomalies has also advanced. 10 Thus, the decision-making risk-reward assessment process cannot be taken lightly.
Ethical issues must be addressed carefully in the informed consent process. It is essential that the decision to go ahead with the maternal-fetal surgery be based on informed, autonomous, and voluntary consent. 8 The informed consent process itself can be broken into 3 discrete elements: (1) disclosure from physician to the patient of adequate information concerning the patient's condition and its management; (2) the patient's understanding of that information; and (3) a voluntary patient decision to authorize or refuse proposed procedures. 11 The ethical considerations of maternal-fetal surgery have been an area of attention and debate for many decades. As fetal surgery becomes widely accepted, offered routinely as a treatment option, and performed for both lethal and nonlethal indications at a growing number of institutions, those discussions have experienced a recent surge. In general, the concept of a healthy individual undergoing a surgical procedure, and thus its associated morbid and mortal risks, solely for the medical benefit of another is inherently controversial. In light of several donor deaths resulting from living liver transplantation, the impetus to adequately address the critical question of equipoise in any treatment involving "2"patients has intensified. It will be interesting to follow this comparison of the ethical considerations of maternal-fetal surgery to those of living donor liver transplantation. To either support or void the recommendation that, given the parallels the ethical dilemmas maternal-fetal surgery and living donor liver transplantation pose, the rigid guidelines for informed consent, donor selection and evaluation, and requirement of additional accreditation standards for medical centers offering the procedure, all of which have all been developed for the latter, can be and likely should be extended to maternal-fetal surgery (L. Diana, personal communication, 2006).
MULTIDISCIPLINARY COLLABORATIVE APPROACH TO FETAL THERAPY
It was obvious from the beginning that the enterprise of fetal diagnosis and therapy could never get off the ground unless a few clinicians from widely disparate backgrounds and specialties learned to work closely together in ways that had really not been achieved previously. Members of the team include a perinatologist, neonatologist, pediatric surgeon, sonologist, anesthesiologist, operating room and perinatal nurse specialists, physiologist, technicians, a social worker, and a nurse coordinator who can serve as a liaison for the family.
In many instances, time is of the essence with fetal surgery cases. Whether it is that the legal window to opt for termination of the pregnancy termination is closing, or that delays could allow an accelerating or aggressively deleterious problem to contribute to substantial fetal morbidity and even mortality, the team together with the family must often work together without the luxury of time. For maximum possible ben- efit, fetal surgery candidates should be identified and referred before 23 weeks' gestation. The earlier the referral, the more adequate the time is to allow the fetal surgery team to consider the clinical situation carefully, allow the family to consider its options carefully, and to perform appropriately timed interventions. Figure 1 outlines the multidisciplinary approach to specific interventions developed by the fetal surgery team.
Considerations for collaborative care planning
When fetal surgery is chosen, the clinical case may be broken down into 2 phases: (1) diagnosis and (2) information and decision making.
Diagnosis
The diagnostic phase generally covers the period from the time of referral to the fetal treatment center through the evaluation process. For families, this typically is a waiting period, first for an appointment and then for the array of diagnostic and test results. Many families find this the most difficult time. In an attempt to alleviate fears and provide information to families, the team developed a unique Web site: http://fetus. ucsfmedicalcenter.org/. The Web site utilizes 3 media to educate families: written text, videos, and animation. Patients are encouraged to review the content on the Web site for their specific diagnosis to gain knowledge of their fetal condition and assist them in formulating questions at their evaluation.
The Fetal Treatment Center team recognizes that the family is both coming to grips with the loss of a normal pregnancy and facing the anxiety of an uncertain future. Nursing plays a key role during this time both in coordinating the arrangements for the evaluation and by providing information and reassurance to the family. In this phase, the family's concerns will often center on the diagnosis and cause of the fetal problem, even so far as to wonder and dwell on their possible personal role in contributing to the problem. Families need explicit reassurance on all fronts. Their feelings of grief, fear, uncertainty, and perhaps guilt must be addressed with compassion and facts, but in no way should their feelings or experience be diminished.
Information and decision making
Before deciding what is best for them the family meets with all members of the team who provide detailed information about preoperative, intraoperative, and perioperative care, answer questions, and address concerns. The family also meets privately with the perinatal social worker, who makes a psychosocial assessment and evaluates the family's ability to cope. This evaluation includes assessment of the marital relationship and other family dynamics, available support systems, coping strategies used in previous crises, previous experience of loss, current stress factors, unemployment or financial constraints, and other health problems. Collectively, this information assists in the team's assessment of the family's ability to adapt and cope, and what additional resources may be helpful.
Once the differential diagnoses are established, members of the fetal treatment team present family with its treatment options. These options may include termination of the pregnancy (if it is still early enough in gestation), surgical intervention, or waiting to term delivery for standard postnatal care. Whether invasive therapy should be offered and recommended or offered but not recommended, the team considers this issue at this point. Such therapy should be offered and recommended only if 2 criteria are met: (1) The therapy is judged to have a high likelihood of being life saving or of preventing serious, irreversible disease, injury, or disability for the fetus and the child to come; and (2) the therapy has a low risk of mortality and low risk of fetal morbidity. Although maternal risk is expected to be low or manageable, any surgical procedure carries some risk of morbidity and mortality, and this risk and all associated risks should be stated explicitly in the counseling and informed consent processes.
The family's worst fears are often confirmed during the decision-making phase. As the grief reaction begins, the family's emotions and feelings may become more intense. In many cases, they also must face a myriad of considerations: religious, moral, and ethical dilemmas, as well as financial and practical implications. The informed consent procedure must seek to minimize family and societal pressures, such that choices are made completely voluntarily and without duress. The individual obtaining the consent should make sure that the woman is alone and that some of the outside pressure is removed. 8 As can clearly be seen, the fetus with an anomaly requires the attention of a team of specialists. 12 There are medical and ethical issues that require the balancing of risks and benefits for not 1, but 2 patients, the mother and the fetus. 13, 14 Fetal surgery requires a collective approach to caregiving, and meaningful collaboration must exist and remain in place among the fetal treatment center's multidisciplinary team of pediatric surgeon, perinatal obstetrician, sonographer, anesthesiologist, operating room and obstetrical nurses, geneticist, social worker, ethicist, and nurse coordinator.
FETAL THERAPY: ON THE HORIZON
As previously mentioned, treatment strategies for genetic problems in particular are being attempted through fetal therapy. For example, errors of metabolism are being treated by providing the mother with medication, vitamins, or the specific substance the fetus lacks, to be passed through the placenta to the fetus. Other therapeutic strategies have been aimed at correcting blood incompatibility problems.
One new fetal therapy with exciting potential is the treatment for severe combined immunodeficiency or SCID, a disorder that impels infants and children with essentially nonfunctional immune systems to live in protective bubbles to shield them from exposure to infectious agents. SCID is also associated with a high mortality rate. Fetal stem cell transplantation has been successful in treating this condition in utero; however, its application in medicine may be in jeopardy as controversy surrounding the general enterprise of fetal stem cell research mounts. It may be possible to avert opposition to the use of fetal cells and tissue and further explore this treatment approach by harvesting stem cells from a parent and transfusing them through the umbilical cord of the fetus. From the umbilical cord, these transplanted cells migrate to the fetal bone marrow, where abundant space exists and their presence accommodated, as the liver and not the marrow is the primary hematopoietic organ during gestational development. Stem cell transplantation takes advantage of the fetus's preimmune state, which allows these transplanted cells to engraft, proliferate, replace the fetal stem cells, and finally differentiate into the various cell types of the immune system. 15, 16 One published report described successful treatment of SCID by in utero transplantation of paternal bone marrow. At more than 11 months posttransplant, the patient's bone marrow showed presence of donor-derived cells in sufficient numbers that strongly suggested successful engraftment of donor hematopoietic stem cells and, thus, a possible cure for SCID. 17 If this therapy continues to be successful long-term, it may then be attempted for other forms of hemoglobinopathies, particularly sickle cell anemia and thalassemia. In summary, there are many potential advantages to fetal transplantation, including the ability to engraft unmatched donor cells without the need for immunosuppression or ablation of the recipient's bone marrow. Early transplantation allows immunologic reconstitution to begin before the disease manifests itself with devastating, irreversible, or even fatal clinical consequences. In addition, development of donor-specific tolerance could allow the recipient to receive postnatal transplants from the same donor sometime later in life. A national network of cord blood banks already in place gives families the opportunity to save cord blood for use later in life in the event that an immune problem arises. 18 There are exciting innovations in fetal therapy and the delivery of care, which take advantage of information technology. The "Fetal Treatment Center -Inside Online Review & Diagnosis" is the center's new online program that will allow families and their local physicians to interact directly with the team without leaving their home. Through Inside, patients can receive an expedient evaluation. Families seeking a second opinion can join the online patient program via the Fetal Treatment Center Web site. Once enrolled, patients receive their own personalized secure Inside account, through which, they can upload digital ultrasound files and reports they receive from their referring physicians for review by the team of specialists. The team provides patients a report detailing our second opinion evaluation. Depending on the complexity of the patient's evaluation, the patient will be contacted by either a phone consultation or a live Web video consultation. Further involvement by the UCSF team is dependent on individual patient needs. For some complex problems, it may be recommended that patients travel to the clinical site for detailed monitoring and treatment. More often, patients can continue to be monitored by their own physician or specialists closer to home. In this latter situation, UCSF can be a resource for patients through their personal Inside portal and provide further review with changes in the pregnancy.
Future of fetal surgery
Increasingly sophisticated techniques for prenatal diagnosis and increasingly innovative, sometimes controversial treatment strategies have revolutionized the field of fetal medicine. The fetus has come a long way from its enigmatic yet impersonal identity to a unique individual with medical and surgical problems that can be diagnosed and treated. The relatively young but eventful history of fetal surgical intervention offers new hope for the fetus with an isolated congenital malformation. The great promise of fetal therapy is that, for some diseases, the earliest possible intervention (ie, before birth) produces the best possible outcome (ie, the best quality of life for the resources expended). However, the potential for cost-effective, preventive fetal therapy can be subverted by misguided clinical applications, such as performing a complex in utero procedure that "half saves"an otherwise-doomed fetus for a life of intensive (and financially and emotionally expensive) care. Enthusiasm for fetal intervention must be tempered by reverence for the interests of the mother and family, by careful study of the disease in experimental fetal animals and untreated human fetuses, and by a willingness to abandon therapy that does not prove both efficacious and cost-effective in properly controlled trials.
SUMMARY
The number of fetal disorders and structural defects that can be identified at a stage early enough to allow thoughtful, timely treatment options is steadily growing. With improvements in prenatal diagnosis, increasing numbers of patients may choose the option to treat fetuses with major problems either pre-or postnatally. 19 For many fetal defects, strict selection criteria for in utero intervention have been defined, the anesthestic and tocolytic protocols worked out, and the surgical techniques for hysterotomy and fetal surgery developed. Indeed, the fetus has become a bona fide patient in our lifetime 12 (Fig 2) . The primary goal of this article has been to describe the history of fetal diagnosis and treatment and, in particular, fetal surgery. As this field rapidly evolves, expands, and broadens the options for treatment, more healthcare professionals will be approached by both colleagues and patients with questions on fetal intervention, including surgery. In this redefined clinical milieu, nurses must have a basic understanding of this burgeoning area of medicine, including its associated technology and perhaps even the new ethical considerations it poses. For nurses, fetal therapy presents complex challenges. Nurses offer counseling, educational, organizational, and technical expertise and skills to the treatment team, patients, and families. They also provide significant insight on the ethical considerations that arise in this evolving field. This article recognizes the critical, complex, and often difficult role the nurses fulfill in fetal treatment, acting as both patient advocate and fetal treatment team representative. The responsibilities are complex, and the nurses who fulfill them must be able to weigh, balance, interpret, and act on a variety of issues from a multifaceted, informed perspective. This article, then, is an acknowledgment of the talent, intellect, skill, and compassion that nursing professionals bring to the field of fetal treatment.
